#Gold #Nasdaq The US markets appear to have struggled through the anniversary of 1987’s Black Monday without severe trauma, so we decided to check on drug maker Pfizers potentials. The company claim to be mass producing a Covid-19 vaccine, awaiting approvals prior to launching their fix once national regulatory authorities give a green light. Apparently, they already are running trials on 44,000 people, hoping the product shall prove effecting and deemed safe. If this is the case, they’re intending to be able to supply health services immediately.
Overall, the company ambition is to provide health services with 1.3 billion dozes worldwide, a sales potential which must surely effect the pharmaceuticals share price! Equally, we couldn’t resist the temptation to find who makes the single use syringes required. It turns out to be a company called ApiJect, unfortunately not listed on trading exchanges.
Presently trading around 37.8 dollars, Pfizer looks like their share price need exceed 39.6 to become properly interesting. Such a movement looks capable of triggering an initial movement toward the 45 dollar level. Visually, we’d suspect some hesitation at such a point, due to previous highs. However, with closure above 45 dollars, things become quite useful as our next target level becomes the 50 dollar mark. An achievement such as this should prove extremely significant, launching the share into “all time high” territory where a longer term attraction shall be viewed as 62 dollars.
There’s no doubt this has potentials, so the big question will be; “shall it move on rumour of regulatory approvals or shall it move once they start shifting product?” Regardless, it appears worth watching in the hope they don’t foul up. Any excuse to reverse the share below 30 dollars risks producing some fairly extreme trauma, threatening a cascade down to 20 dollars initially with secondary, when broken, at 10 dollars.
|Time Issued||Market||Price At Issue||Short Entry||Fast Exit||Slow Exit||Stop||Long Entry||Fast Exit||Slow Exit||Stop||Prior|